TP53 and breast cancer: In addition, these analyses showed no differences in mRNA levels: (i) among the PAM50 subtypes of BC; (ii) among specific stages of the tumor; (iii) in metastatic vs. no metastatic tumors; (iv) in TP53 mutated tumors vs. TP53 wild-type tumors [Figure 4].